• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 453231 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413809831 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413809831 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Hot Stock: EnteroMedics, Shares Gain 7.2% (ETRM)

Published on Tue, 03/05/2013 - 13:23
By Adrienne Chilton

EnteroMedics (NASDAQ:ETRM) is one of today's best performing penny stocks, up 7.2% to $0.95 on 1.1x average daily volume. Thus far today, EnteroMedics has traded 1.6 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (7.2% to the Dow's 1.0%) and outperformed the S&P 500 (7.2% to the S&P's 1.0%) during today's trading.

EnteroMedics has overhead space with shares priced $0.95, or 76.9% below the average consensus analyst price target of $4.12. The stock should find initial resistance at its 50-day moving average (MA) of $2.15 and further resistance at its 200-day MA of $3.04.

In the past 52 weeks, EnteroMedics share prices have been bracketed by a low of $0.81 and a high of $4.40 and are now at $0.95, 18% above that low price. The 200-day and 50-day moving averages have moved 0.95% lower and 3.99% lower over the past week, respectively.

EnteroMedics Inc. is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of Photronics Underperformed its ...

Below are five companies in the Semiconductor Equipment industry that underperformed ye ...

Analysis of Relative Performance in the ...

Here are 5 stocks in the Retail REITs industry ranked by performance. We compiled the ...

Shares of Krispy Kreme Doughnuts Underpe...

Below are five companies in the Restaurants industry that underperformed yesterday on a ...

Bottom 5 Companies in the Residential RE...

Here are 5 stocks in the Residential REITs industry ranked by performance. We compiled ...

Shares of M&T Bank Underperformed its Pe...

Analysis was conducted on the Regional Banks industry to measure relative performance t ...

Shares of MBIA Underperformed its Peers ...

Below are five companies in the Property & Casualty Insurance industry that underperfor ...

Shares of First Majestic Silver Underper...

Here are 5 stocks in the Precious Metals & Minerals industry ranked by performance. We ...

Bottom 5 Companies in the Personal Produ...

Analysis was conducted on the Personal Products industry to measure relative performanc ...